Evidence map›Paper›PMID 42797608›Full record

ArticleVaccines2026

Characterization of Seasonal Trivalent Influenza Vaccine Formulated with Different Ratios (

Daniela Cajado-Carvalho, Paulo Newton Tonolli, Verônica de Moraes Manzato, Lívia Mendonça Munhoz Dati, Mahyumi Fujimori, Patrícia Antonia Estima Abreu, Christian Savio Silva, Vitor Anselmo Sakihara, Bianca Pereira Carvalho Holanda, Douglas Gonçalves de Macedo and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Daniela Cajado-CarvalhoBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.ORCID 0000-0001-9234-1758
Paulo Newton TonolliBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.ORCID 0000-0002-9547-9477
Verônica de Moraes ManzatoBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Lívia Mendonça Munhoz DatiBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.ORCID 0000-0002-6303-2144
Mahyumi FujimoriBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Patrícia Antonia Estima AbreuBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Christian Savio SilvaBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Vitor Anselmo SakiharaBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Bianca Pereira Carvalho HolandaBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Douglas Gonçalves de MacedoBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Priscila ComoneBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Alexandre BimboBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Esper George KallásBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.ORCID 0000-0003-2026-6925
Ricardo das Neves OliveiraBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Milena Apetito AkamatsuBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.
Paulo Lee HoBioindustrial Center, Butantan Institute, and Butantan Foundation, Sao Paulo 05503-900, SP, Brazil.ORCID 0000-0003-3652-241X

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 309741/2023-8Conselho Nacional de Desenvolvimento Científico e Tecnológico 444400/2023-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/07040-1Fundação de Amparo à Pesquisa do Estado de São Paulo 2024/01094-3
6 · The paper itself

Abstract

BACKGROUND/

objectivesAdjuvanted influenza vaccines are critical to enhance immune responses in high-risk populations, such as the elderly. While initial studies relied on a two-vial system with antigen and adjuvant mixing prior to immunization, this study evaluated the feasibility, immunogenicity, and 12-month stability of a one-vial formulation combining a Trivalent Influenza Vaccine (TIV) with the locally produced squalene-based oil-in-water emulsion IB160.

methodsFormulations were evaluated by testing TIV:IB160 (

resultsThe 2:1 and 1:1 (

conclusionsOne- and two-vial formulations are viable, stable, and highly immunogenic alternatives for adjuvanted TIV in 2:1 and 1:1 (

Indexed as

adjuvant IB160formulation strategiesTIV

Identifiers

PMID42797608
PMCPMC13611202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.